Last reviewed · How we verify

Comparator: Comvax

Merck Sharp & Dohme LLC · Phase 3 active Biologic

Comvax is a combination vaccine that provides immunization against hepatitis B virus and Haemophilus influenzae type b (Hib) by stimulating the immune system to produce protective antibodies against both pathogens.

Comvax is a combination vaccine that provides immunization against hepatitis B virus and Haemophilus influenzae type b (Hib) by stimulating the immune system to produce protective antibodies against both pathogens. Used for Immunization against hepatitis B virus infection, Immunization against Haemophilus influenzae type b (Hib) infection.

At a glance

Generic nameComparator: Comvax
SponsorMerck Sharp & Dohme LLC
Drug classCombination vaccine
TargetHepatitis B surface antigen; Haemophilus influenzae type b polysaccharide
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

Comvax contains recombinant hepatitis B surface antigen and Hib polysaccharide conjugate, which work together to induce humoral immune responses. The vaccine primes B cells and T cells to recognize and respond to these pathogens, providing long-term protection against hepatitis B infection and invasive Hib disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: